1. tv52898
2. jesacoyote77
3. supper3638
4. dmchof94
5. ftbensoldier
1.jesacoyote77 04/17/2018
Basilea licenses late-stage oncology drug candidate derazantinib from ArQule
2.supper3638 06/13/2018
Oppenheimer initiates as an outperform, $7PT
3.jesacoyote77 04/17/2018
early? nah
4.tv52898 02/22/2018
seems accurate
5.dmchof94 02/22/2018
6.dmchof94 04/17/2018
Looking to add some
7.supper3638 04/17/2018
Enters into license agreement with Basilea Pharmaceutica; Basilea will make an upfront payment to ArQule of …
8.supper3638 02/07/2018
ArQule and Roivant Sciences initiate a collaboration to pursue the development of derazantinib in Greater Ch…
9.jesacoyote77 02/04/2018
B. Riley FBR, Inc. raises to buy
10.jesacoyote77 02/22/2018
Wow, this is a double
NEW since the last time you visited this board.
Currently a TOP 10 POST for this board.
Currently a TOP 5 RESEARCHER for this board.
Specific post has replies to it.
A Researcher you are currently FOLLOWING
Other Researchers rate this post HIGH
Other Researchers rate this post LOW